Camrelizumab
- Generic Name
- Camrelizumab
- Drug Type
- Biotech
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- Conditions
- Lung Cancer Squamous CellLung Cancer Stage IVPD-1 AntibodyChemotherapy Effect
- Interventions
- Drug: The placebo
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT03668496
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03666728
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03645876
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT03605706
- Locations
- 🇨🇳
81 Hospital Nanjing, Nanjing, Jiangsu, China
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT03603756
- Locations
- 🇨🇳
Jing Huang, Beijing, China
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 41
- Registration Number
- NCT03601598
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT03558191
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 42
- Registration Number
- NCT03557411
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 10
- Registration Number
- NCT03527251
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 450
- Registration Number
- NCT03427827
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangzhou Medical University Cancer Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.